genOway Improves its Growth With Major Japanese Biopharmaceutical Companies
News Jun 14, 2010
genOway announces strong growth of its business with major Japanese biopharmaceutical companies
The three Japanese biopharmaceutical companies, now customers of genOway, rank among the top ten of the nation’s biopharmaceutical industry. The amount of the active contracts just exceeded €400,000.
These agreements cover the development and delivery of genetically modified animal models and particularly humanized models dedicated to pharmaceutical compound testing. Other contractual details were not disclosed.
Alexandre Fraichard, CEO of genOway, declared: “Japanese biopharmaceutical industry is beginning to show signs of recovery. We were able to drop back on the market since the second half of 2009 and are very pleased that three of the largest Japanese biopharmaceutical companies now make use of our services and added value solutions. It is very important for us to attend sustainably this market, the second in size after the United States. In fact, we are very confident in signing several contracts in Japan in the coming trimesters.”
China is poised to introduce a new regulation on gene editing in humans. A draft of the country’s new civil code lists human genes and embryos in a section on personality rights to be protected. Experiments on genes in adults or embryos that endanger human health or violate ethical norms can accordingly be seen as a violation of a person’s fundamental rights.READ MORE